All Activity

You have done a great job. I will definitely dig it and personally recommend to my friends. I am confident they will be benefited from this site. calculus 3 problems

Her dedication to grassroots activism and community engagement truly embodies the spirit of making a difference. As we drive forward in our own journeys, let’s channel that same passion and energy into our initiatives, just like in Drive Mad! Together, we can connect the dots and create impactful change in our communities.

You have performed a great job on this article. It’s very precise and highly qualitative. You have even managed to make it readable and easy to read. You have some real writing talent. Thank you so much. UFABET เว็บตรง

I read that Post and got it fine and informative. UFABET123

If you’re exploring casino platforms that balance classic vibes with modern play, https://aussiecasinoonline.com.au/casinos/rtg gives a solid overview of destinations powered by Real Time Gaming. These casinos are known for their wide range of pokies, engaging table games, and smooth, reliable performance across devices. What makes them appealing is not just the variety of games, but also user‑friendly interfaces and generally generous bonus offers that add extra value to your play. Whether you’re chasing big wins or just want a fun, straightforward gaming experience, this collection of RTG sites is worth checking out if you enjoy diverse gameplay and trusted platforms.

“We cannot balance state budgets on the backs of one industry. Excessive taxation drives consumers back to the illicit market and shrinks the legal one.” By Katherine Dailey, Michigan Advance Genesee County Sheriff and Democratic gubernatorial candidate Chris Swanson came out strongly in opposition to the 24 percent cannabis tax passed as a part of the Fiscal Year 2026 budget to pay for Gov. Gretchen Whitmer’s (D) plan to fund road repairs statewide. In a video posted to Facebook on Friday evening, Swanson promised that, if elected, he would work to repeal the tax saying that it is “not fair and equitable” to an industry that provides goods and services, as well as jobs, for the state of Michigan. Swanson’s campaign added in a press release that the tax “undermines both the legal market and the intent of voter-approved legalization,” citing the 2018 ballot initiative vote that legalized cannabis in the state of Michigan. “As Governor, I will work to roll back the 24 percent wholesale excise tax to ensure fairness and equity,” he continued in the press release. “We cannot balance state budgets on the backs of one industry. Excessive taxation drives consumers back to the illicit market and shrinks the legal one.” “I’ve never been a fan of solving budgetary problems by targeting one industry, and that’s what’s happened,” Swanson said in the video. “The people spoke. This is an industry that’s here to stay. and anything that tries to disrupt that is gonna be non-negotiable for this administration. And on top of that, we’re gonna keep this from spilling over to the black market, where these can lead into other, more dangerous situations. So we’re just gonna make sure this industry is taken care of.” The tax passed narrowly through the state Legislature in early October and went into effect at the start of 2026, and has been heavily criticized—and even taken to court—by cannabis industry leaders for what they see as harms to the industry and the small businesses that make it up. Swanson’s press release also quoted Michigan Cannabis Industry Association Executive Director Robin Schneider as praising his opposition to the tax, especially as a law enforcement officer focused on keeping the industry out of the black market. “Candidate Chris Swanson came out publicly against the 24 percent wholesale tax,” Schneider said. “It is now our responsibility to create the momentum behind the messaging that he is bold enough to carry for us.” Swanson also emphasized in the press release that he still intends to fund the types of infrastructure projects that the cannabis tax is currently set to fund. “This is about doing what’s right for Michigan. Even by rolling back this tax, I am 100 percent committed to funding all future road and bridge projects. That’s a priority too,” he said. “Supporting a fair system protects people, strengthens small businesses and respects the voters who made their voices heard.” Swanson has trailed in polling and campaign fundraising in the primary behind Secretary of State Jocelyn Benson (D), but has continued campaigning ahead of the August primary. This story was first published by Michigan Advance. The post Michigan Sheriff Running For Governor Pledges To Repeal Marijuana Tax Increase appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Hawaii senators are sending a message to the governor, state attorney general and health department to recognize their “clear legislative stance” in support of requesting an exemption from the Drug Enforcement Administration (DEA) stipulating that Hawaii is permitted to run its medical cannabis program without federal interference. Members of the Senate Health and Human Services Committee on Monday approved a pair of resolutions that address the state-federal cannabis policy disconnect, with a push to have state officials exercise their authority to request a DEA exemption under the Controlled Substances Act (CSA) with respect to its medical marijuana law. The “legal disharmony” resulting from the underlying policy conflict has “created a layered legal and economic gray area, in which patients and dispensaries must violate federal law to participate, with prosecution protection entirely dependent upon the non-enforcement of federal law,” the companion Senate resolution and Senate concurrent resolution say. This is not the first time that the legislature has advanced such resolutions—and the language of the latest versions reflects a sense of frustration that the Department of Health (DOH) failed to follow through on lawmakers’ 2021 directive to request the cannabis exemption. The governor and state attorney general also have the power to make that exemption request, the measures note. Under the current system, the “legal disparities between the state and federal regulation of cannabis threaten employment, firearms registration, inter-island transport, housing, hospice care, and safe and affordable access for tens of thousands of Hawaii’s medical cannabis patients,” the legislation says, adding that the conflicting policies further “discourage hundreds of thousands of potential medical cannabis patients from enrolling in Hawaii’s Medical Cannabis Program for fear of federal repercussions.” To effectively protect the state’s medical cannabis patient population, Hawaii could apply for the DEA exception “so that registered patients could participate in Hawaii’s Medical Cannabis Program without being exposed to federal prosecution or discrimination,” SR 141 and SCR 150 continue. Under the concurrent resolution adopted during the 2021 session, DOH received a request from lawmakers to apply for that exemption in hopes of receiving “formal written acknowledgement that the listing of marihuana, marihuana extract, and tetrahydrocannabinols as controlled substances in Federal Schedule I does not apply to the protected activities in Hawaii Revised Statutes.” However, “despite this clear legislative stance, the Department of Health, along with the Governor and Attorney General who also have the discretion to apply for the exemption, have yet to take any action,” the measures say. Notably, the resolutions that cleared the Senate committee on Monday also point out that President Donald Trump signed an executive order in December to “expedite the federal rescheduling of cannabis to Schedule III.” Therefore, there’s urgent need to “protect Hawaii’s medical cannabis program and the state’s authority over the intrastate medical use of cannabis.” The resolutions say the governor is “respectfully requested to act on House Concurrent Resolution 132, Regular Session of 2021 and pursue with the Drug Enforcement Administration an exemption from federal controlled substance regulation for registered medical cannabis patients in Hawaii.” Also, “it is also requested that registration waivers from the Drug Enforcement Administration for state-licensed dispensaries under Chapter 21 United States Code, section 822(d) are pursued for the intrastate production and distribution of medical cannabis,” and DOH is additionally “requested to provide updates to the Legislature as they become available.” Relatedly, in 2020, DEA rejected a petition to exempt Iowa from enforcement actions related to its medical cannabis program that was filed by an activist, Carl Olsen, who also filed a lawsuit against the governor, arguing that the state had unnecessarily delayed submitting that request as prescribed under legislation that passed that year. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Back in Hawaii, although senators recently approved a bill to legalize low-dose and low-potency marijuana, the legislation didn’t advance through required steps before a key deadline, and so it is dead for the year. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, SB 2421, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. Those actions comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. Earlier this month, a Hawaii Senate committee separately passed legislation to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. Meanwhile, a Hawaii House committee last week approved a Senate-passed bill that would create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. Legislation to allow qualifying patients to access medical marijuana at health facilities is also advancing this session. The post Hawaii Senators Pass Resolutions Seeking Federal Medical Marijuana Exemption From DEA appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A coalition of anti-marijuana organizations is suing the Trump administration over a novel initiative set to launch this week to widen the availability of CBD and THC for certain patients by covering hemp-derived products under select federal health insurance programs. Smart Approaches to Marijuana (SAM) and nine other drug prevention groups on Monday filed a lawsuit in the U.S. District Court for the District of Columbia, challenging the legality of the cannabis program—which is being facilitated by the Centers for Medicare & Medicaid Services (CMS)—and seeking a temporary restraining order to immediately halt the process. The filing names CMS Administrator Mehmet Oz and U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. as defendants in the lawsuit. The lawsuit comes as CMS is set to start covering CBD and THC products as a Substance Access Beneficiary Engagement Incentive (BEI) beginning on Wednesday. Under the BEI, patients enrolled in specific federal health insurance programs could have up to $500 worth of hemp-derived products covered each year. The CBD-focused plan will also allow a certain amount of THC in products, but the agency said earlier this month the rules are subject to change if federal hemp policy changes, as is currently expected under a law set to take effect later this year. SAM and the other organizations—including the Cannabis Impact Prevention Coalition, Drug Free American Foundation and Save Our Society From Drugs—made several arguments in support of legal intervention to prevent the cannabidiol BEI from moving forward. Much of the complaint focuses on alleged violations of administrative rules to provide the treatment, which they point out has not received Food and Drug Administration (FDA) approval. CMS didn’t publish a notice of proposed rulemaking for the cannabis BEI that would have afforded the public with a comment period to weigh in, and the agency’s initiative runs counter to a separate final rule it issued last year that “declared cannabis products ineligible for supplemental Medicare coverage for chronically ill patients,” the prohibitionist plaintiffs said. Beyond those alleged violations of the Administrative Procedure Act (APA), the groups noted that CMS described a BEI for CBD containing a maximum THC concentration that exceeds what would constitute federally legal hemp under a policy that’s set to be implemented in November. The filing says the program would additionally violate the Social Security Act (SSA), which “does not allow CMS to sanction the possession and use of illegal and dangerous Schedule I substances by Medicare patients without clear congressional authorization.” “CMS’s action represents an unprecedented and unlawful assertion of binding decision-making authority that will profoundly affect the health of elderly Americans,” SAM and the other organizations said in their complaint. “CMS took this action without the guardrails imposed by the administrative process, without any reasoned explanation, in conflict with the agency’s own recent APA-compliant determination, and without statutory authority.” The program is anti-science, likely in violation of federal law, and will seriously damage public health. Lose-lose-lose . . . except for the addiction industries who pushed for it. Marijuana is linked to heart disease, dementia, and mental illness. CBD is linked to liver… — Smart Approaches to Marijuana (@learnaboutsam) March 31, 2026 Therefore, the plaintiffs are asking the federal court to vacate the BEI, deem in unlawful and permanently enjoin the implementation of the policy. In the interim, they are seeking a temporary restraining order, preliminary injunction and stay of agency action amid the judicial review. As far as legal standing is concerned, SAM said the BEI “provides marijuana products via a medical source,” so its expenses related to efforts opposing a separate cannabis rescheduling process “has been rendered essentially moot.” “SAM’s injury is not abstract policy disagreement but concrete impairment of specific programmatic activities with a consequent drain on organizational resources,” it said. The filing adds that one of the plaintiffs in the case—SAM donor and consultant David Evans—would also be personally injured by the CMS policy action because he’s a Medicare recipient who was deprived of the ability to submit a public comment on the BEI and whose “healthcare relationship” with CMS is altered by the initiative. The prayer for relief section of the lawsuit requests that the court 1) declare that the BEI was adopted in violation of APA notice-and-comment requirements, 2) declare the BEI is “arbitrary, capricious, and abuse of discretion, or otherwise not in accordance with the law,” 3) declare the BEI exceeds CMS’s statutory authority, 4) vacate the BEI, 5) permanently enjoin the implementation or enforcement of the initiative and 6) award legal fees to the defendants. “Let’s be perfectly clear: raw marijuana—especially in the form of non-FDA approved products like tinctures and gummies—is not medicine,” SAM CEO Kevin A. Sabet said in a press release. “While there are some FDA-approved medical uses for CBD and THC, like Epidiolex, these prescription medications are already covered under insurance.” “What CMS will cover, if this is allowed to go through, are products sold at gas stations and convenience stores that are nothing more than snake oil. These are not regulated or tested by the FDA and do not fall under the [generally recognized as safe] standard,” he said. “It is unclear how they would be regulated, if at all, and how patients would be educated about potential side effects or medication interactions.” The CBD initiative is being implemented in response to a directive Trump signed in December that also called on the attorney general to expeditiously complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). That wouldn’t federally legalize it, but it would remove certain research barriers associated with Schedule I drugs and also allow state-licensed marijuana businesses to take federal tax deductions. For its part, CMS posted an update earlier this month detailing how certain of its “Innovation Center” models will facilitate the pilot program providing coverage to regulated, hemp-derived cannabidiol. Participants would be required to ensure that CBD is sourced from “a legally compliant source and high-quality farm,” prepared as an oral solution and tested for cannabinoid content so that available products contain no more than 0.3 percent delta-9 THC by dry weight and up to 3 milligrams of total THC per serving. CMS said that centers participating in one of three models that receive substance access BEI will be able to “consult with eligible beneficiaries about the possible use of eligible hemp products to improve symptom control.” “Participants implementing this BEI may elect to furnish such hemp products up to $500 a year, per eligible beneficiary, subject to model requirements and safeguards,” it said, while emphasizing that Medicare “does not pay the participant for the products, and beneficiaries should not be asked to submit a Medicare claim for the product.” The three eligible innovation center models are CMS’s ACO REACH Model, Enhancing Oncology Model and Long-term Enhance ACO Design (LEAD) Model. For the first two, participants can elect to utilize the BEI for CBD coverage starting on April 1. For LEAD participants, the start date is January 1, 2027. Participating organizations under those models must first elect the substance access BEI and then produce a CMS implementation plan that describes “the specific eligible hemp product(s) and dosing information, the amount/frequency of distribution, beneficiary eligibility criteria, safeguards/oversight, and other requirements outlined in participation agreements.” Those plans would need to receive CMS approval before participants could offer cannabidiol coverage. After initial details about the initiative were revealed this month, CMS faced questions about the potential impact of a law set to take effect in November that would redefine hemp in a way that would strictly limit the types of cannabis products that are currently permitted under the 2018 Farm Bill that Trump signed in his first term. That law expressly prohibits hemp derivatives containing more than 0.4 milligrams of total THC per container, which industry stakeholders say would effectively eradicate the consumable hemp market. Here’s how CMS is defining hemp products allowed through its substance access BEI: “Eligible hemp products are limited to federally legal hemp-derived products containing no more than 0.3 percent delta-9 THC and expressly excludes inhalable products, any products containing more than 3 mg per serving of tetrohydrocannabinols (such as delta-8-tetrahyrdocannabinol, delta-10-tetrahyrdocannabinol, and tetrahydrocannabinolic acid) in an orally administered form, and any products containing cannabinoids not naturally produced or capable of being produced by or in the cannabis plant during its cultivation.” The agency acknowledged that its definition complies with the 2018 Farm Bill provisions and noted that its coverage plan “does not override the Controlled Substances Act or authorize Schedule I substances.” “To be eligible, hemp products must also comply with applicable state and local laws,” CMS said, raising additional questions about potential regulatory complications as multiple states have proactively moved to restrict hemp product availability in anticipation of the pending federal policy change. “If the legal limits on hemp-derived products changes…CMS will adjust its definition in accordance with the law.” CMS further explained that cannabinoid products “must be furnished and provided directly by a qualified physician affiliated with the participant organization, as specified by the model participation agreements,” and model participants “cannot instruct beneficiaries to purchase retail products and submit receipts for reimbursement under the BEI.” To be approved to provide CBD coverage, model participants must 1) meet federal, state and local “production, quality and safety laws and other mandated standards,” 2) be sourced from legally compliant farms “consistent with 2018 Farm Bill hemp requirements” and 3) be tested for cannabinoid content, as well as “contaminants and microbial hazards.” The details about the rules for the CBD pilot program came weeks after a co-founder of the hemp company Charolette’s Web, which has been collaborating with CMS, said the agency had already finalized its plans for federal health insurance coverage of cannabidiol. Bill Morachnick, CEO of Charlotte’s Web, said in a press release on Monday that they are “grateful for CMS’s thoughtful approach in expanding access and creating space for responsible, evidence‑based hemp wellness conversations in clinical settings.” “This program aligns with our mission to advance safe, high‑quality, science‑backed hemp options for consumers, and we remain committed to supporting sensible legislation that protects patients and strengthens the integrity of our industry,” he said. “The updated guidance from CMS represents an important step in strengthening how hemp-based options are considered within care settings,” Morachnick said in a separate statement. “By reinforcing a science-driven framework centered on safety, quality, and transparency, it creates a clearer path for responsible integration into patient care. We see this as meaningful progress toward expanding access to trusted, non-intoxicating hemp solutions in a way that aligns with both clinical standards and patient needs.” Oz, the CMS administrator, explained in December that the policy change will “allow millions of Americans on Medicare to become eligible to receive CBD as early as April of next year—and at no charge if their doctors recommend them.” He added that Medicare Advantage insurers CMS has contacted are “also agreeing to consider CBD to be used for the 34 million Americans that they cover.” As previously described by the administrator, the plan would involved those 65 and older who qualify for Medicare, but the specific qualifying conditions weren’t detailed. There were repeated mentions of chronic pain, specifically related to cancer, but it’s possible the CBD eligibility criteria includes additional conditions. In its latest update, CMS said patients with disqualifying conditions under the Innovation Center models, as well as those who are pregnant or breastfeeding, could not receive CBD. They must also be at least 18 years old to participate. At the signing ceremony for the marijuana and hemp executive order Trump signed in December, Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced a video about the benefits of cannabidiol for seniors that the president shared on Truth Social last year and who apparently has pressed Trump to enact reform to expand cannabis access. CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. The rule as proposed would amend regulations, which currently state that any “cannabis products” cannot be covered. The policy would prevent coverage for only “cannabis products that are illegal under applicable state or federal law, including the Federal Food, Drug, and Cosmetic Act.” Since hemp and its derivatives like CBD are federally legal, the change suggests patients in states where such products are legal could make valid insurance claims to pay for the alternative treatment option, as long as the product is also federally legal. Meanwhile, following the White House announcement in December, Oz spoke with NewsNation about the policy change, responding to a question about how the broader marijuana rescheduling decision squares with the Trump administration’s aggressive efforts to stymie the flow of other illicit drugs, particularly fentanyl. “We think they fit hand in hand,” he said. “This is really about researching—specifically CBD, which is hemp-derived endocannabinoids [sic]—are actually worthy of Americans using them,” he said. “It’s hard to do some of this work, especially with medical marijuana. And this is not about legalization of marijuana.” “There is no legalization language at all,” he added. “It’s about rescheduling this class of product so that it can be researched more readily.” The idea that marijuana has no medical value, as its currently defined as a Schedule I drug, is “just patently wrong for marijuana,” he said, noting that FDA has approved certain cannabis-based drugs for conditions such as epilepsy “that work quite nicely.” “That belief that it should be Schedule I is just an incorrect place to put it,” he said. “Schedule III seemed to make sense to the president. He argued that it allows us to do the research more readily.” “We’re finding a way to allow Medicare beneficiaries to get access to some of these products. And so, within Medicare, we have the ability, for the first time ever—and we delivered on this promise to the president today—to allow doctors to recommend hemp-derived CBD for patients who have cancer, for example, and have a lot of pain from that.” The administrator said surveys show a majority of seniors who take CBD for pain management find it beneficial, and the White House wants to “make it easier for patients to access this” and allow them to access the cannabinoid at “no charge” through the federal health insurance program. Oz took a different tone last month when he warned that “there are going to be consequences” as more Americans choose marijuana over alcohol—including problems caused by “high-dose hemp and CBD.” In the background, HHS and FDA recently submitted proposed regulations concerning CBD enforcement and compliance with the White House Office of Management and Budget’s (OMB) Office of Information and Regulatory Affairs (OIRA). Multiple cannabis industry stakeholders have been granted meetings with OIRA to discuss the proposal this week. Read the federal lawsuit concerning the CMS cannabidiol health coverage initiative below: Photo courtesy of Kimzy Nanney. The post Anti-Marijuana Groups File Lawsuit To Block Trump Administration’s Hemp CBD And THC Medicare Coverage Plan appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Idaho Senate has approved a resolution urging voters in the state to “reject” an ongoing effort to place an initiative to legalize medical marijuana on the November ballot. The measure, sponsored by the Senate State Affairs Committee, claims that cannabis legalization in other states has led to a host of harms, including “increased cartel activity, development of black market marijuana production, human trafficking, and increased crime rates” as well as “increased rates of serious health issues,” environmental harms and “safety concerns on job sites.” SCR 127, which was adopted on the Senate floor on Monday in a voice vote, further argues that the measure would not only increase costs to the state but that its list of approved medical conditions is “so broad that almost anyone could qualify.” “The Idaho Medical Cannabis Act lacks safeguards to such an extent that it would effectively legalize widespread recreational use of marijuana,” the resolution now headed for consideration in the House of Representatives claims. “The legalization of marijuana would have devastating impacts on Idaho children and their families… The Legislature urges the citizens of Idaho to reject any effort to bring the Idaho Medical Cannabis Act to the ballot.” A statement of purpose filed with the legislation says it “addresses the devastating impact that legalizing marijuana has had on other states” and “identifies the significant problems” with the ballot initiative. The Natural Medicine Alliance of Idaho (NMAI), which is leading the effort to place the legalization measure before voters this November, pushed back against the resolution. “Idahoans deserve to vote on this issue, and we are confident we will be able to get it in front of them this November to do just that,” Amanda Watson, a spokesperson for the group, said in a press release last week when the resolution was filed. “There are thousands of people across Idaho with stories like Dr. Tunney’s and they deserve dignified care and the option to choose an alternative to opioids. NMAI has operating field offices in every corner of the state and we are actively recruiting more team members in Coeur d’Alene, Meridian, Boise, Twin Falls, Pocatello and Idaho Falls. We are not taking our foot off the gas until the final bell rings.” Contrary to the claims made about marijuana reform in the legislative resolution, advocates often point to data showing that legalizing and regulating cannabis diminishes the size of the illegal market and has not led to increases in youth use. Sen. Ben Toews (R) said on the Senate floor ahead of the vote on Monday that “with good reason, Idaho is one of four states in which marijuana is fully illegal, and we should urge Idahoans to reject any effort to bring the medical cannabis act to the November 2026 ballot.” “Idaho sovereignty should not be compromised by an addiction for profit business dominated by secretive donors and out of state consultants and drug interests,” he said. In contrast, Sen. Melissa Wintrow (D) rose to share a personal story about the medical benefits of cannabis. “When my mom was dying of cancer and wasting away emaciated and wouldn’t eat because she was just didn’t have the appetite, she was in another state, and we talked about medical cannabis to get her appetite up and so she would gain weight and could withstand the cancer treatments,” she said. “And I can remember how desperate I was and my mother. So I think before we just throw out the use of medical marijuana, that we should really think about that.” NMAI recently released an analysis showing that Idaho could see more than $100 million worth of medical marijuana sold on an annual basis and up to $28 million in new yearly revenue for state coffers if voters approve the legalization initiative. The group also announced that it’s collected enough signatures for the cannabis measure to exceed the statewide threshold for ballot qualification. But because it’s unclear how many signatures the campaign has collected to far are valid and whether activists have met a separate requirement for regional distribution of petitions, NMAI is continuing to hold signature gathering events across the state to widen their coalition of supporters in the run-up to the May 1 submission deadline. Amanda Watson, NMAI’s communications lead, told Marijuana Moment last week that organizers “feel very confident we will qualify for the ballot in November.” As of Tuesday, NMAI has collected more than 77,000 signatures total—exceeding the 70,725 statewide requirement for valid petitions—according to the campaign’s website. To be certified for the ballot, the team also needs to submit signatures from 6 percent of registered voters from at least 18 of the state’s 35 legislative districts. Meanwhile, teams of paid and volunteer petitioners are being deployed throughout the state to target high-traffic areas to gather signatures, and NMAI’s website features a map showing where registered voters can go to sign. The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market. Here are the main provisions of the Idaho Medical Cannabis Act: Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain. Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month. The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total. Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance. State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program. There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions. It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option. “We believe Idahoans deserve access to legal, compassionate, natural care right here at home,” NMAI’s website says. “Our mission is to give patients a legal pathway to natural medicine that can ease suffering and restore dignity without the fear of addiction.” “The Idaho Medical Cannabis Act is our first step forward. It creates a safe, tightly regulated medical program that allows qualified Idahoans to seek medical cannabis treatment with a valid diagnosis from a healthcare provider,” it says. “It supports Idaho agriculture, generates tax revenue to reinvest locally, and ensures that patients can find natural relief.” The campaign last month also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents. Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.” After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults. Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful. Meanwhile, voters this year will see a different kind of proposal on the ballot: A constitutional amendment that the legislature approved to make it so only lawmakers could legalize marijuana or other controlled substances. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Legislators separately held a hearing last March to discuss a bill to enact medical cannabis legalization legislatively, but there hasn’t been meaningful action on the issue in the months since. Separately, a bill from Rep. Bruce Skaug (R) last year would have set a $420 mandatory minimum fine for cannabis possession, removing judges’ discretion to apply lower penalties. Skaug said the bill, which ultimately stalled in committee, would send the message that Idaho is tough on marijuana. House lawmakers also passed a bill to ban marijuana advertisements, though the Senate later defeated the measure. Photo courtesy of Max Pixel. The post Idaho Senate Passes Resolution Urging Voters Not To Sign Medical Marijuana Ballot Petitions appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Despite carrying the consequences of criminalization, and being key sustainers of the legal industry as workers and consumers, Latinos are underrepresented as business owners in the industry.” By Jason Ortiz and Maritza Perez Medina, Latino Cannabis Alliance One of the first reported deaths resulting from the Trump administration’s renewed immigration raids in 2025 was that of Jaime Alanís Garcia—a beloved husband, father and provider. Jaime was a longtime farmworker, laboring at a state-legal cannabis farm in California on the fateful day he tragically fell from a building as federal immigration agents swarmed his workplace. The moment of Jaime’s death sent shock waves through the Latino community, particularly for those of us who work in the marijuana space. Yet, to our frustration, the greater cannabis community was largely silent. This tragic event forced many of us who work within the cannabis ecosystem to realize that we did not have an organized and credible Latino voice to express our anger and mobilize our people toward action—while our labor, our business, our language and our culture have helped to lay the foundation for the cannabis industry as we know it today. Despite our outsized impact on the industry and our disproportionate rates of arrest, incarceration and deportation, there have been few organized national efforts to educate, empower and mobilize the Latino community toward securing our place in the legal industry and to demand justice for the damage done to our communities from the war on drugs. To correct this and ensure that we have a powerful voice to express our demands for inclusion and justice, we formed the Latino Cannabis Alliance (LCA). With the Trump Administration ramping up harassment of Latino youth and bragging about marijuana-based deportations, our work is more important than ever. The LCA aims to serve as a central forum for analysis, commentary and guidance on cannabis issues from a Latino lens, creating a foundation for deeper representation across the industry and the broader policy landscape. From this foundation, we seek to build bridges across diverse Latino communities and cultivate meaningful relationships with Latino lawmakers. Recognizing the transnational identity of our communities, we aspire to strengthen international connections across Latin America and foster cross-border collaboration grounded in equity, justice, and cultural understanding. The Latino Cannabis Alliance is composed of community leaders with a diverse range of skills, countries of origin and roles within the cannabis ecosystem. We are policy advocates, academics, attorneys, community organizers and story tellers who aim to use our talents to enrich and serve our communities. Combined, we have decades of experience in the cannabis reform space. The launch of the LCA is long overdue. The first anti-marijuana laws in the U.S. were passed to target Mexican migrants and other people of color. Harry Anslinger, the initial architect of the U.S. war on drugs, relied on racism to help pass the first cannabis prohibition law in Congress—the Marijuana Tax Act of 1937. In fact, Anslinger intentionally called cannabis “marijuana” to make it sound “Spanish” and “foreign,” and to associate the plant with Mexican migrants in the public view. To this day, cannabis is still referred to as marijuana in the U.S. federal code. The toll of decades-long marijuana prohibition in Latino communities has been devastating. Latinos are overrepresented in marijuana arrest and incarceration rates throughout the country. In 2023, the U.S. Sentencing Commission reported that Hispanics made up 70.8 percent of all people sentenced for federal marijuana possession in the previous five fiscal years. Arrest and conviction records block people from accessing jobs, housing, and benefits, among other consequences, detrimentally impacting families and communities. Moreover, marijuana criminalization has been a key driver of immigrant detention and deportation. Between 2002 and 2020,127,387 people were deported for marijuana-related offenses. At least 600 individuals were deported in 2025 for marijuana-related convictions, an estimate that is likely an undercount. Despite carrying the consequences of criminalization, and being key sustainers of the legal industry as workers and consumers, Latinos are underrepresented as business owners in the industry. This is due to many reasons, including: some people cannot participate in the industry due to previous convictions; their immigration status will not allow them to participate safely; or the cost of entry is too high and capital is unavailable. The LCA aspires to close these gaps so that people no longer suffer under the weight of criminal or immigration consequences, or unjust barriers to ownership in the industry. This work has always been necessary, but it is more urgent than ever in today’s political climate. The global war on drugs will only end once we unite in solidarity aqui y alla. We have started the process of building an organized, collective force ready to light a fire within all Latinos who care about cannabis or are impacted by cannabis policy. Together, we will bring the heat until our communities have the justice and opportunities we deserve. Jason Ortiz is vice president of the Latino Cannabis Alliance and is as director of strategic initiatives at Last Prisoner Project. Maritza Perez Medina is director of policy for the Latino Cannabis Alliance and is director of federal affairs at Drug Policy Alliance. The post Now Is The Time for Latinos In Cannabis To Flex Our Power (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I’m going to read this. I’ll be sure to come back. thanks for sharing. and also This article gives the light in which we can observe the reality. this is very nice one and gives indepth information. thanks for this nice article... เว็บแทงบอล

The New Hampshire House of Representatives has approved an amended bill to establish a psilocybin advisory board to study pathways to allow patients to access the novel therapy—though lawmakers separately rejected an effort to revive separate legislation aimed at protecting gun rights for medical marijuana patients. Members took up the psilocybin and cannabis measures on Thursday, significantly scaling back the bipartisan psychedelics bill from Rep. Buzz Scherr (D) that would have in its initial form given certain patients legal access to psilocybin-assisted therapy. The amended version to create an advisory group to explore the issue passed the full chamber and now heads to the Senate for consideration. The medical marijuana and firearms legislation from Rep. Tom Mannion (R), meanwhile, was briefly considered on the floor, but a motion to take the bill off the table failed in a 81-270 vote. That proposal would make it so a person’s status as a registered medical cannabis patient in the state would not infringe on their right to purchase or possess guns under state law. The revised psilocybin bill represents a setback for advocates, as the House passed the initial version last month that would have created a regulatory pathway for patients with certain conditions to access the psychedelic for therapeutic use through a program overseen by the state Department of Health and Human Services (DHSS). Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order to advance to the Senate. The committee deemed the bill inexpedient to legislate, and when it got the floor for the second time on Thursday, members overturned that recommendation and then adopted the major change that only contemplates a potential regulated access model instead, with an advisory board tasked with studying the issue. That dialed-back version ultimately passed. “The medical community has always recognized that patients exist with serious conditions that are very resistant to effective treatment,” a statement of purpose says. “Recently, research has begun to show that certain of those patients have had positive results with the closely supervised use of psilocybin for treatment.” “The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention,” the bill, HB 1809, says. On marijuana reform, the legislation from Mannion and bipartisan cosponsors, HB 1446, would preserve gun rights for medical cannabis patients in the state, reaffirming their right under the state constitution even if they continue to face a federal ban on possession or buying firearms persists. The U.S. Supreme Court is actively reviewing a case that could lift that prohibition after hearing oral arguments last month. “This bill ensures that our therapeutic cannabis patients are no longer treated as second-class citizens or differently from other patients being treated with different medications,” Rep. Billie Butler (D) said before the vote on the motion. Also this month, New Hampshire lawmakers effectively killed bills to legalize marijuana and allow the therapeutic use of psilocybin by not bringing them up for floor votes ahead of a key deadline. One bill from Rep. Jonah Wheeler (D) would have put a constitutional amendment on the state ballot to let voters decide if they want to legalize marijuana for adults 21 and older, allowing them to “possess a modest amount of cannabis for their personal use.” Members of the House Criminal Justice and Public Safety Committee took up that legislation in January. It was ultimately deemed inexpedient to legislate by a majority of the panel, but in New Hampshire all bills still have the opportunity to advance to the floor even with negative committee recommendations. Another cannabis legalization bill that didn’t get a floor vote in the House by deadline was HB 1235-FN from Rep. Jared Sullivan (D) and five bipartisan cosponsors. The measure was also designated as inexpedient to legislate by the Criminal Justice and Public Safety Committee. Sullivan also filed separate legislation this session that would have legalized adult-use cannabis through a regulated sales model, with additional provisions to provide relief for those who’ve previously been criminalized over marijuana. That bill already passed the House this year, but it was then promptly killed in the Senate. The House this month further declined to take up a Republican-led bill from Rep. Michael Moffett (R) that would have permitted the regulated use of psilocybin in a medically supervised setting. To qualify for psilocybin treatment, a patient 21 or older would have needed to be diagnosed with treatment-resistant depression, PTSD, substance misuse disorder, a terminal illness requiring end-of-life care or any other condition authorized by DHHS. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, Gov. Kelly Ayotte (R) has already threatened to veto any marijuana legalization bill that reaches her desk, though the constitutional amendment proposal would not require gubernatorial action. The governor said in August that her position on the reform would not change even if the federal government moved forward with rescheduling the plant. Since then, President Donald Trump has directed the attorney general to finalize the process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). At a committee meeting last year, Sullivan ultimately made a persuasive argument for advancing his legalization bill, pointing out that the House has repeatedly passed similar legislation and that the chamber should stand its ground, forcing the Senate and governor to again go on record with their opposition to a policy popular among voters. “We know where it’s going to go. Let’s send a virtue signal,” Sullivan said. “Let them be the ones that are pissing off voters who care about this.” In the Senate, the Judiciary Committee in January also took up a bill from Sen. Donovan Fenton (D) that would allow adults over the age of 21 to legally possess up to four ounces of cannabis in plant form and 20 grams of concentrated cannabis products, as well as other products containing no more than 2,000 milligrams of THC. Last June, the New Hampshire Senate voted to scrap compromise legislation that would have lowered the state’s criminal penalty for first-time psilocybin possession while also creating mandatory minimum sentences around fentanyl. As originally introduced, the legislation would have completely removed penalties around obtaining, purchasing, transporting, possessing or using psilocybin, effectively legalizing it on a noncommercial basis. However a House committee amended the bill before unanimously advancing it last March. Image element courtesy of Kristie Gianopulos. The post New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To Protect Medical Marijuana Patients’ Gun Rights appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

White House CBD meetings; AOC slams marijuana & psychedelics scheduling; TX lawmakers’ hemp & ibogaine reviews; Cannabis taxes op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The White House Office of Management and Budget has scheduled several additional meetings for this week about a CBD products compliance and enforcement policy that the Food and Drug Administration submitted for approval. Rep. Alexandria Ocasio-Cortez (D-NY) said the federal system for classifying marijuana and other drugs has “fallen short”—noting that “our law says that these drugs have zero medical application, but the science says something else.” “The wealth of medical research shows that these are potential treatments for treatment-resistant PTSD, traumatic brain injuries—but the schedule classification really prevents researchers from continuing to do work on this.” New York Gov. Kathy Hochul (D) is celebrating the five-year anniversary of marijuana legalization—touting $3.3 billion in sales, more than 600 operational licensed cannabis shops and achievements in promoting social equity and criminal justice reform. Texas’s lieutenant governor issued a mandate for the Senate Health and Human Services Committee to study the impact of cannabis and THC products during the legislative interim, while the House speaker directed the Public Health Committee to monitor implementation of legislation to establish a consortium to conduct ibogaine drug development clinical trials. LeafLink’s Rodney Holcombe argues in a new Marijuana Moment op-ed that calls to increase cannabis taxes from the New York Times editorial board and others “overlook how high effective tax burdens already are in many states.” “Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis.” / FEDERAL The Centers for Disease Control and Prevention published a study finding that an “analysis of 2015–2025 National Poison Data System data found an increase of approximately 1,200% in kratom-related exposure reports (from 258 to 3,434), including a marked surge in 2025.” Sen. Amy Klobuchar (D-MN) discussed her push to delay the federal recriminalization of hemp THC products. / STATES Former Texas Gov. Rick Perry (R) is reportedly writing a book about psychedelics aimed at a Christian audience. A Pennsylvania representative discussed his bill to strengthen medical cannabis testing protocols. Florida officials accused a petitioner for a marijuana legalization initiative of submitting nearly 1,600 fraudulent signatures. Michigan officials are facing another lawsuit challenging a new marijuana wholesale tax. New York’s top marijuana regulator discussed the five-year anniversary of legalization. Missouri regulators are seeking a new vendor to manage the state’s marijuana licensing and tracking program. The Arkansas Medical Marijuana Commission will meet on Thursday. The Rhode Island Cannabis Advisory Board will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Oakland, California Cannabis Regulatory Commission will meet on Thursday. / INTERNATIONAL Germany’s interior minister called the country’s marijuana legalization policy a “shitty law.” South African officials gave lawmakers an update on efforts to develop a commercially viable cannabis and hemp industry. / SCIENCE & HEALTH A study found that “the adoption of [recreational cannabis legalization] in US states, beyond only [medical cannabis legalization], may help to reduce the size of illegal cannabis markets, or there may be shifting law enforcement seizure priorities in those states.” A review concluded that “MDMA-[assisted therapy] was associated with reductions in PTSD symptom severity and improvements in dissociative symptoms and global functioning.” / ADVOCACY, OPINION & ANALYSIS The Latino Cannabis Alliance is a new advocacy organization that aims to represent Latinos in the marijuana reform movement and industry. / BUSINESS Vireo Growth Inc. said its memorandum of understanding with The Scotts Miracle-Gro Company to acquire The Hawthorne Gardening Company LLC could close within five business days, subject to certain conditions. Illinois dispensaries sold $12.5 million worth of medical cannabis products in February. / CULTURE The Daily Show’s Josh Johnson joked about the Army’s move to loosen marijuana restrictions for new recruits. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Celebrating 5 years of legal cannabis in New York (Newsletter: March 31, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

In an era where online multiplayer can be stressful, the game's playful nature fosters a positive gaming environment by encouraging players to celebrate their victories and laugh at their exploits, as seen in monkey market.

With Tag Game, players can choose from a variety of mythical characters, each adding unique charm and excitement to the overall experience.

Kart Bros io is the best free racing game I've played. No intrusive ads during gameplay, just pure, focused racing. The instant browser access with no download makes Kart Bros io 2026 my go-to for a quick and satisfying session.https://www.kartbrosio.app/

The White House now scheduled a total of four meetings with cannabis industry and research stakeholders this week to discuss a proposed enforcement policy for CBD products. The Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) announced earlier this month that it plans to review yet-unpublished guidance titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy” that was submitted by the Food and Drug Administration (FDA). Interested parties are able to request meetings to discuss the issue—and now four meetings have been set for April 1-2. David Heldreth, CEO of Panacea Plant Sciences, was the first to secure a meeting with OIRA, and he told Marijuana Moment last week he intends to use the opportunity to encourage FDA to develop more holistic guidance around CBD that goes beyond isolates of the cannabinoid. Since then, the White House has accepted requests for meetings to discuss the yet-to-be-published CBD rule with Trent Woloveck of the multi-state cannabis operator Jushi Holdings on Wednesday, as well as Mackie Barch of Story Cannabis and Iowa hemp farmer Earl Ramey on Thursday. All of this comes months before changes to federal hemp laws are set to significantly shake up the industry, with a ban on most consumable cannabinoid products containing THC taking effect in November. As part of the underlying law, FDA was tasked with publishing a list of known cannabinoids, but it missed a congressionally imposed deadline to fulfill that obligation and it’s unclear when that list will ultimately be furnished. Some have speculated that the enforcement policy guidance that OIRA is reviewing concerns the executive order President Donald Trump signed in December to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), which also included provisions directing the Centers for Medicare & Medicaid Services (CMS) to create a pathway for CBD health care coverage. To that end, CMS did recently shared new details about that plan, which would make it so patients enrolled in select insurance programs could have up to $500 of hemp-derived products covered each year beginning as early as Wednesday. The CBD-focused plan will also allow a certain amount of THC in products, but the agency said the planned rules are subject to change if federal hemp policy changes, as is currently expected under the law set to take effect in November. Participants would be required to ensure that CBD is sourced from “a legally compliant source and high-quality farm,” prepared as an oral solution and tested for cannabinoid content so that available products contain no more than 0.3 percent delta-9 THC by dry weight and up to 3 milligrams of total THC per serving. CMS said that centers participating in one of three models that receive substance access Beneficiary Engagement Incentives (BEI) will be able to “consult with eligible beneficiaries about the possible use of eligible hemp products to improve symptom control.” The new details about the rules for the CBD pilot program come weeks after a co-founder of the hemp company Charlotte’s Web, which has been collaborating with CMS, said the agency had already finalized its plans for federal health insurance coverage of cannabidiol. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — While CMS implemented an earlier final rule last April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency is now revising that policy. CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. Meanwhile, with respect to the marijuana components of Trump’s December executive order, Attorney General Pam Bondi was directed to expeditiously finalize the proposal to reschedule cannabis, which would not federally legalize it but would remove certain research barriers and let state-licensed marijuana businesses take federal tax deductions they’re currently barred from under an Internal Revenue Service (IRS) code known as 280E. That rescheduling proposal remains pending, however. The post White House Schedules More Meetings On Cannabis Product Enforcement Policy From FDA For This Week appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The governor of New York is marking the five-year anniversary of adult-use marijuana legalization in the state, touting $3.3 billion in retail sales, the opening of more than 600 licensed cannabis shops and achievements in promoting social equity in the industry while taking steps to mitigate the illicit market. In a press release on Friday, Gov. Kathy Hochul (D) said “New York committed to building a cannabis market rooted in equity, safety, and opportunity” when the state enacted the Marihuana Regulation and Taxation Act five years ago. “We are creating new pathways for small businesses while aggressively shutting down illicit shops that threaten public safety and undermine our legal market,” the governor, who has helped lead the implementation of the cannabis reform and celebrated its milestones along the way, said. “Our focus is clear: protect consumers, support legal businesses, and ensure this industry grows the right way.” In addition to seeing $3.3 billion in recreational marijuana sales over the past half-decade, New York officials have also licensed 2,161 cannabis businesses across the supply chain, including 610 retailers that are now operational. The 600th marijuana shop, Pure Blossoms, recently opened its doors in Manhattan. “New York’s cannabis market is demonstrating that growth and equity are not mutually exclusive,” Office of Cannabis Management (OCM) Acting Executive Director John Kagia said. “With more than $3 billion in sales, a majority of licenses held by Social and Economic Equity applicants, and a rapidly expanding retail footprint, the State is building a market that is both economically viable and intentionally inclusive.” “These outcomes reflect a deliberate approach to ensuring long-term stability, accountability, and opportunity across the industry as we continue to strengthen the market and expand access in the years ahead,” he said. All told, more than half (56 percent) of adult-use marijuana licensees have go to Social and Economic Equity (SEE) applicants, which surpasses the state’s statutory goal. Those SEE licensees include 57 percent that have gone to women-owned businesses and 51 percent to minority-owned businesses. Also with respect to equity achievements, the state is promoting the fact that more than 400,000 cannabis-related convictions are been deemed eligible for expungement, and over 200,000 have already been sealed. Another 107,000 cases have been “suppressed pending sealing,” and nobody is currently incarcerated in state prison for a marijuana-related offense alone, the governor’s release says. Further, the state has distributed $5 million in funding for community reinvestment through a fund supported by marijuana tax dollars, and another $5 million is currently available in the fund that aims to promote youth development, workforce training, housing opportunities and public health projects for people in areas disproportionately impacted by criminalization. The MRTA “centered on equity, economic opportunity and restorative justice,” Assembly Majority Leader Crystal Peoples-Stokes (D), who a key champion of adult-use legalization in the state, said. “These core principles remain my priority as the legal cannabis market continues to mature.” “We, as legislators, and leaders in the state, have a duty to take steps to correct the harm that was done by the War on Drugs. As the adult-use cannabis market in New York State continues to grow, we must not lose sight of the equity tenants of MRTA,” she said. “New York State’s cannabis market is setting the standard that the rest of the country should follow and I am immensely proud of that.” Sen. Erik Bottcher (D) said that, five years into the state’s legalization experience, “we’re seeing small businesses and entrepreneurs finding their footing as well as and investments that are reaching communities that were disproportionately impacted in the past.” “The opening of new, licensed dispensaries and the shutdown of illegal dispensaries reflects that forward momentum,” he said. “Thank you to Governor Hochul for ensuring that as the industry continues to grow we remain focused on supporting responsible operators and customers alike.” In January, meanwhile, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. The OCM annual report also notes that Hochul signed legislation into law that expands the state’s medical cannabis program by improving patient access and “updating the program framework to better meet patient needs statewide.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, New York senators recently approved a bill related to reciprocity for out-of-state medical marijuana patients and the availability of pre-rolled joints in the medical cannabis market—even though the state has already enacted those reforms separately. Last month, the sponsor of the bill separately introduced legislation that would allow New York liquor and wine stores to obtain a permit to sell low-dose cannabis-infused drinks at their businesses. Also, the governor of New York last month signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. In January, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. Also, the governor of New York last month signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. Photo courtesy of Philip Steffan. The post New York Governor Marks Five-Year Anniversary Of Marijuana Legalization, With Over $3.3 Billion In Sales And 610 Licensed Retailers appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis.” By Rodney Holcombe, LeafLink In recent piece, The New York Times editorial board called for a federal tax on cannabis and urged states to raise their own taxes to “dollars per joint, not cents.” That argument assumes cannabis is lightly taxed today—but across the country, the opposite is true. Taxes on legal cannabis are higher than almost every industry in the United States and have generated nearly $25 billion since adult-use sales commenced in 2014. Despite these rates, efforts to increase cannabis levies are continuing to gain steam. In 2025 alone, Maryland, Minnesota, Maine, Ohio, Michigan and California attempted to raise or expand cannabis taxes. This year, Colorado and Oklahoma are looking to do the same. Many of those proposals emerged as lawmakers confronted budget shortfalls and the expiration of federal pandemic aid. Cannabis has increasingly been treated as an untapped source of revenue. In several large markets, cannabis taxes are layered on top of one another. Excise taxes are combined with state sales taxes, wholesale taxes, local taxes and, in some cases, potency-based taxes. In states such as Illinois, Michigan and Washington, the effective burden can exceed 40 percent. This is in addition to the federal tax burden cannabis businesses carry under §280E, which limits their ability to deduct ordinary operating expenses. These structures are straining the legal market. High tax burdens are contributing to business closures (particularly among smaller operators) and pushing many consumers to the illicit market. According to publicly available data, several highly taxed states, including California, Colorado, Illinois, and Washington, have experienced year-over-year declines in adult-use sales and industry job losses in recent years. At the same time, the illicit markets across these states remain entrenched. In California, one of the nation’s oldest legal cannabis markets, estimates suggest that roughly 60 percent of sales still occur outside the regulated system. Higher taxes do not eliminate consumer demand. They simply change where consumers buy their cannabis. Licensed businesses pay for testing, packaging, compliance systems, labor and sometimes local licensing. Unregulated sellers do not. When the legal price rises too far above the illicit alternative, price-sensitive consumers shift accordingly. That weakens the regulated market that legalization was intended to build. When tax increases take effect, the impact shows up quickly in wholesale pricing pressure, retailer margin compression, and shifts in purchasing behavior. The cannabis industry is still new, but data tell us that the type of tax matters as much as the rate. THC-based potency taxes have created compliance and administrative challenges in states such as Connecticut and Illinois. Because liability is tied to measured THC content rather than price, minor variations in laboratory testing can alter tax obligations. That adds cost and uncertainty for operators. It also influences pricing in ways that do not necessarily advance public health goals. New York eliminated its potency tax and replaced it with a distributor-level excise tax after determining the structure was not working as intended. States with lower and simpler effective tax structures have generally shown more stable performance. Markets with competitive total burdens and several years of operating history have tended to demonstrate steadier sales and job growth. While federal prohibition and hemp-derived THC competition complicate conditions nationwide, tax policy remains fully within state control. Recent developments illustrate how sensitive these markets are to tax changes. In 2025, San Diego raised its local cannabis tax to 10 percent, double the rate when it was first introduced. Data show that the tax brought in less revenue than projected, likely as a result of consumers seeking out alternate channels for purchasing products. In Michigan, a 24 percent wholesale tax took effect this year atop the existing excise and sales taxes. The state’s January 2026 sales revenue decreased 16 percent from December and falls below January 2025 levels. Cannabis tax revenue funds many meaningful programs across the country, but these programs depend on a functional legal market that can actually generate that revenue. If tax rates push consumers back to the illicit market, this revenue simply won’t materialize. The issue is not whether cannabis should be taxed. It is whether tax systems are calibrated in a way that allows the legal market to function as intended. Calls to raise taxes to “dollars per joint” overlook how high effective tax burdens already are in many states. When licensed operators are forced to compete with illicit sellers, higher taxes risk slowing the transition of consumers into regulated channels and weakening this still nascent industry. If policymakers are evaluating the performance of legalization or creating a framework for a new market, tax design should be a critical part of that conversation. Excessive and complex tax systems make it harder for licensed businesses to compete and for states to achieve their public health, safety, and revenue goals. Rodney Holcombe is the vice president of Public Policy and Communications at LeafLink. The post Too High To Thrive: Excessive Cannabis Taxes Are Undermining Legal Markets (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Texas Senate and House leaders are directing lawmakers to study issues related to cannabis products and psychedelic therapy during the legislature’s interim in preparation for a new session scheduled to begin in early 2027. Lt. Gov. Dan Patrick (R), who oversees the Senate, pushed to pass legislation last session to ban hemp THC products. The legislation was approved by lawmakers but was later vetoed by Gov. Greg Abbott (R). But Patrick isn’t giving up. In his list of 2026 interim legislative charges released on Friday, he’s directing the Senate Health and Human Services Committee. Under a heading titled, “Addressing Societal Impacts of THC Product Consumption,” the lieutenant governor charged the panel to “study the impact of THC on increased health care costs, mental health emergency detentions, and the risk of being diagnosed with a THC-induced psychotic disorder.” The committee should “make recommendations to decrease health care and criminal justice costs,” the directive says. My statement announcing 2026 Interim Charges to the Texas Senate. To read the interim charges, click here: https://t.co/KtW2BUX7Rx#txlege pic.twitter.com/9fMdjiXvMX — Office of the Lieutenant Governor Dan Patrick (@LtGovTX) March 27, 2026 Separately, House Speaker Dustin Burrows (R) is directing his chamber’s Public Health Committee to spend time before the next session monitoring the “implementation and associated rulemaking” for legislation enacted last year to support clinical trials aimed at developing the psychedelic ibogaine into a legal prescription medicine to treat substance use disorders and other mental health conditions. The list of interim charges issued by the speaker on Thursday notes that the bill that Abbott signed into law relates to “the establishment of a consortium to conduct United States Food and Drug Administration’s drug development clinical trials with ibogaine to secure the administration’s approval of the medication’s use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.” Today, I issued interim charges for House committees of the 89th Texas Legislature to guide our work ahead of the next legislative session in 2027. These priorities build on our recent progress, strengthen accountability in government, reduce inefficiencies, and ensure key… pic.twitter.com/woyc1E0xjv — Dustin Burrows (@Burrows4TX) March 26, 2026 Earlier this month, the Texas Department of State Health Services (DSHS) adopted new hemp product rules that will effectively ban smokable hemp THCA flower. Specifically, the agency approved language requiring hemp products to be tested for “total THC” content, including THCA, which means most cannabis flower would be considered non-compliant with limitations imposed under state law. Meanwhile this month, Texas voters approved a marijuana legalization question that appeared on the state’s Democratic primary ballot. As part of the primary election, each major party was able to place several non-binding propositions on the ballot that allow voters show how they feel on key issues. The Texas Democratic Party used one of its propositions to find out where the electorate stands on legalizing cannabis and whether past convictions should be expunged. For what it’s worth, a statewide poll released last month found that Texas voters don’t like how state leaders and lawmakers have handled marijuana and THC policy issues. In the survey, a plurality of voters (40 percent) said they disapprove of how their elected officials have approached the issue, according to the survey. Just 29 percent said they approve of how cannabis issues have been handled, while 31 percent said they didn’t have an opinion one way or another. A separate poll released last year found that a plurality of Texas voters want the state’s marijuana laws to be made “less strict.” And among the legislative items lawmakers considered during recent special sessions, voters say a proposal to address hemp regulations was among the least important. With respect to ibogaine under the bill the governor signed, Texas will retain a commercial interest in “all intellectual property that may be generated over the course of the drug development clinical trials,” the legislation says, with an aim of making the state a hub for “ibogaine-related biomedical research, development, treatment, manufacturing, and distribution.” A quarter of revenue taken in by the state from any resulting intellectual property would fund veterans programs. Along with the legislation’s goal of winning federal Food and Drug Administration (FDA) approval as a clinical treatment, the bill says it also seeks “a breakthrough therapy designation for ibogaine”—a designation FDA gives to emerging treatment options that haven’t yet secured agency approval to treat a particular condition. The post Texas Lawmakers Will Study Cannabis And Psychedelics Issues Under New Orders From Senate And House Leaders appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I would like to say that this blog really convinced me to do it! Thanks, very good post. 오피스타

What a thrilling post, you have pointed out some excellent points, I as well believe this is a superb website. I have planned to visit it again and again. live toto

What a thrilling post, you have pointed out some excellent points, I as well believe this is a superb website. I have planned to visit it again and again. pestoto 4d

Rep. Alexandria Ocasio-Cortez (D-NY) tore into the current U.S. drug scheduling system on Thursday—making the case that placing substances like marijuana and LSD in the most restrictive category runs counter to evidence showing their medical potential, hinders research and is associated with criminal penalties that haven’t effectively prevented harms from substance misuse. In some cases, the congresswoman said during a hearing before the House Energy & Commerce Health Subcommittee, classifying drugs as Schedule I under the Controlled Substances Act (CSA) can exacerbate the overdose crisis, leading to the introduction of new, sometimes more dangerous drugs into the illicit marketplace. The panel on Thursday took testimony on a variety of bills aimed at curbing overdose deaths and responding to emerging public health threats posed by illegal drugs such as xylazine and other opioid-like synthetics that are often more potent than the analogues that came before them. Ocasio-Cortez said it was time to “take a step back” and “really explore and examine the scheduling system in the United States as a whole and really how we think about this,” directing her questions to Nabarun Dasgupta, a senior scientist at the University of North Carolina who served as an expert witness for the hearing. Our current drug scheduling system in the U.S. does little to deter drug abuse or overdose rates, but instead hinders research and unfairly criminalizes communities. We need to invest in actual solutions like prevention, treatment, and recovery. pic.twitter.com/CNkfaN795W — Rep. Alexandria Ocasio-Cortez (@RepAOC) March 26, 2026 “We’re often trying to slot in certain substances into our scheduling [and] end up playing a lot of whack-a-mole,” the congresswoman said. “Once you schedule one substance, people then start finding alternatives—and before you know it, people are then starting to overdose on entirely new substances that we didn’t even know existed a couple of years ago.” “In theory, Schedule I drugs are supposed to have no potential for medical use and high risk for abuse and addiction, correct?” she asked Dasgupta, who affirmed that was the case. “There are also specific penalties tied to each schedule. Once a drug gets scheduled, the penalties for possessing that drug can change overnight,” Ocasio-Cortez said. “And so when we look back at the point of scheduling, in about 1970 or so, Congress created this system to try to deter the use of dangerous drugs by applying criminal penalties to the possession of those drugs and scheduling was also intended to ensure safety when these drugs are used in clinical or research settings.” “Now, since this system was established more than 50 years ago, we’ve seen how it’s fallen short. We’ve endured the war on drugs, and we’ve also had a lot of limitations in medical research,” she said before asking the expert to provide examples of drugs currently classified as Schedule I under the CSA. Dasgupta pointed to marijuana, LSD and MDMA, and Ocasio-Cortez followed up by asking for his opinion on whether those three substances meet the definition of having “zero potential medical application.” “I think the medical literature is clear that they do have clinical benefits,” Dasgupta said. The congresswoman had him repeat that point, clarifying that its his assessment that “right now our law says that these drugs have zero medical application, but the science says something else.” “That’s right,” he said. Ocasio-Cortez added that “the wealth of medical research shows that these are potential treatments for treatment-resistant PTSD, traumatic brain injuries—but the schedule classification really prevents researchers from continuing to do work on this, correct?” The scientist again answered in the affirmative. Opponents might counter that narrative by arguing that “people are overdosing on some of these substances, so we still need to schedule them,” the congresswoman said. “But has adding criminal penalties successfully reduced overdose deaths?” Dasgupta answered by pointing to an examples out of Florida, where the state placed xylazine in Schedule I of their own controlled drugs list but then saw overdose deaths from xylazine increase from about 3,700 per year to 6,400 per year. That goes to show that simply scheduling a drug is “not a panacea,” he said. Ocasio-Cortez went on to say that “increasing the scheduling is becoming medically prohibitive for treatments, but then also adding the criminal penalties has not only not reduced overdose, but in the state of Florida, it’s doubled them.” “But I think we’re all still here on the same purpose, right? We want to make sure that we’re protecting people and doing what we can,” she said, asking the witness whether he’s aware of “any methods…that can help us make progress on this.” Dasgupta said, “I mean, I think scheduling does have an important role. I think there just needs to be a lot more flexibility to keep the science in line with the regulatory process. That’s the bottom line.” Of the three Schedule I drugs that the scientist cited at the hearing, the Food and Drug Administration (FDA) has already signaled that they each hold medical potential, with one LSD-like substance, MM120, and the main compound of ecstasy, MDMA, receiving breakthrough therapy status to promote research that could lead to drug development. For marijuana, its time in Schedule I may be coming to an end. After a years-long scientific review led by FDA, former Attorney General Merrick Garland ultimately signed a proposed rule to move cannabis to Schedule III of the CSA. That process wasn’t completed by the end of the Biden administration that initiated it, but President Donald Trump in December signed an executive order directing the current attorney general, Pam Bondi, to expeditiously finalize that rule. As Rep. Steve Cohen (D-TN) noted in a letter sent to Bondi on Friday, however, marijuana remains in Schedule I even three months after the president issued that directive. The congressman is therefore seeking an update from DOJ on the status of its rulemaking. The post AOC Slams Federal Drug Laws That Restrict Marijuana And Psychedelics Despite Their Medical Value appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

My spouse and i shocked while using investigation anyone created to choose this certain release outstanding. Amazing task! 屋根補修